8-K: TherapeuticsMD Appoints New Independent Auditor

TherapeuticsMD, Inc. announced the appointment of Carr, Riggs & Ingram, L.L.C. as its new independent registered public accounting firm, effective January 15, 2026.

Summary

• TherapeuticsMD, Inc. appointed Carr, Riggs & Ingram, L.L.C. (CRI) as its new independent registered public accounting firm, effective January 15, 2026.
• The previous auditor, Berkowitz Pollack Brant Advisors + CPAs (BPB), ceased serving due to CRI's acquisition of certain assets related to BPB's capital markets practice.
• BPB's audit reports for the fiscal years ended December 31, 2024, and December 31, 2023, did not contain adverse opinions, disclaimers, qualifications, or modifications, except for an explanatory paragraph regarding the Company's ability to continue as a going concern.
• There were no disagreements with BPB on accounting principles, financial statement disclosure, or auditing scope/procedure during the fiscal years ended December 31, 2025, and December 31, 2024, through the dismissal date.
• No reportable events occurred with BPB during the fiscal years ended December 31, 2025, and December 31, 2024, through the dismissal date.
• Neither the Company nor anyone on its behalf consulted with CRI regarding accounting principles or audit opinions prior to their appointment.

Sentiment

Score: 3

Explanation: The sentiment is negative primarily due to the disclosure of the 'going concern' explanatory paragraph in the previous auditor's reports, indicating significant financial uncertainty for the company. While the auditor change itself is due to an acquisition and not a disagreement, the underlying financial health concern is paramount.

Positives

• The change in auditor was due to an acquisition of assets by the new firm, rather than a disagreement or performance issue with the previous auditor.
• There were no disagreements or reportable events with the former independent registered public accounting firm, Berkowitz Pollack Brant Advisors + CPAs, during the specified periods.

Negatives

• The previous auditor's reports for the fiscal years ended December 31, 2024, and December 31, 2023, included an explanatory paragraph describing the uncertainty of the Company's ability to continue as a going concern.

Risks

• Uncertainty regarding the Company's ability to continue as a going concern, as highlighted by the explanatory paragraph in the previous auditor's reports for fiscal years ended December 31, 2024, and December 31, 2023.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the change in the independent registered public accounting firm.

Industry Context

Changes in independent registered public accounting firms can occur for various reasons, including mergers and acquisitions within the accounting industry, as is the case here. While the reason for the change is benign, the underlying 'going concern' issue is a significant financial indicator for the company.

Stakeholder Impact

• Shareholders may be negatively impacted by the uncertainty regarding the Company's ability to continue as a going concern, potentially leading to decreased share value.
• Creditors may view the Company as a higher risk due to the going concern uncertainty, potentially affecting future financing terms.

Key Dates

Recommendation

The disclosure of a 'going concern' explanatory paragraph by the previous auditor for two consecutive fiscal years (2023 and 2024) is a critical red flag. This indicates substantial doubt about the company's ability to continue operating, which typically precedes severe financial distress or bankruptcy. Despite the auditor change being due to an acquisition, the underlying financial health issue is paramount and warrants a strong sell recommendation for investors to mitigate potential losses.

Keywords

TherapeuticsMD, auditor change, independent registered public accounting firm, Form 8-K, going concern, corporate governance, financial reporting, SEC filing